Congress Scientific Watch

From ESMO Congress 2023:
Combining prostate-specific membrane antigen-targeted radiotherapy and enzalutamide improves progression-free survival versus enzalutamide alone for high-risk metastatic castration-resistant prostate cancer 

From ESMO Congress 2023:
Patients with progressive non-muscle-invasive bladder cancer and select FGFR mutations have better recurrence-free survival with oral erdafitinib than an investigator’s choice of intravesical chemotherapy

From ESMO Congress 2023:
The benefits of first-line afatinib for nonsquamous non-small-cell lung cancer extend to patients with uncommon sensitizing EGFR mutations 

From the 2023 World Conference on Lung Cancer:
Latest findings from the AEGEAN trial indicate NSCLC surgical outcomes are not affected by perioperative durvalumab but that patients with an EGFR mutation do not benefit

From the 2023 World Conference on Lung Cancer:
Patients with ROS1 fusion-positive non-small-cell lung cancer show ongoing responses to repotrectinib when given as first- or second-line ROS1 tyrosine kinase inhibitor therapy 

From the 2023 World Conference on Lung Cancer:
The addition of platinum-based chemotherapy to first-line osimertinib improves progression-free survival for patients with advanced, EGFR-mutated non-small-cell lung cancer 

From the 2023 World Conference on Lung Cancer:
Randomised controlled trial demonstrates poorer survival and other outcomes with cytoreduction plus chemotherapy than with chemotherapy alone

From ESMO World Congress on Gastrointestinal Cancer 2023:
Bemarituzumab shows survival benefits for patients with advanced gastric adenocarcinoma and high immunohistochemistry expression of FGFR2b

From ESMO World Congress on Gastrointestinal Cancer 2023:
The addition of ipilimumab to nivolumab does not improve the outcome of patients with inoperable or metastatic squamous cell carcinoma of the anus who have progressed after systemic chemoradiation

From ESMO World Congress on Gastrointestinal Cancer 2023:
The LEAP-017 trial did not show an overall survival advantage with lenvatinib plus pembrolizumab versus chemotherapy for microsatellite-stable, mismatch repair-proficient metastatic colorectal cancer

From ESMO World Congress on Gastrointestinal Cancer 2023:
Patients undergoing resection of HER2-positive gastric or oesophagogastric junction cancer may benefit from use of trastuzumab alongside perioperative chemotherapy

From ESMO World Congress on Gastrointestinal Cancer 2023:
Exploratory biomarker analyses show which patients with oesophageal or gastro-oesophageal junction cancer are most likely to receive clinical benefit from adjuvant nivolumab